RxDoctor Payments Data

Maritoni Malvar, MD

Family Medicine · New Castle, PANPI 1255309324

Payments from drug & device makers

$16,669in general payments, 2019–2025

Across 764 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$961
  • GSK$859
  • plus $8K from 35 others

What the payments were for

  • Food & beverage$16,636100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,669 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,391
Medicare patients
28
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$64,229
OzempicSemaglutide27$41,307
MounjaroTirzepatide19$22,308
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$22,279
KerendiaFinerenone16$20,563
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,216
LinzessLinaclotide13$7,263
GemtesaVibegron14$6,695
BelsomraSuvorexant11$4,988
SynthroidLevothyroxine Sodium39$3,275
TradjentaLinagliptin11$2,642
VascepaIcosapent Ethyl13$2,615
Icosapent Ethyl11$2,357
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$2,245
Donepezil Hcl69$1,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,951$75,44568 claims
Novo NordiskOzempic$1,359$41,30727 claims
Lilly USA, LLCMounjaro$961$22,30819 claims
GSKTrelegy Ellipta$859$22,27917 claims
BayerKerendia$797$20,56316 claims
AbbVieLinzess, Synthroid$2,019$10,53752 claims
Sumitomo Pharma America, Inc.Gemtesa$119$6,69514 claims
MerckBelsomra$248$4,98811 claims
Boehringer IngelheimTradjenta$608$2,64211 claims
Almatica Pharma LLCSertraline Hcl$32$27123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →